By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Citigroup has initiated coverage of Illumina with a "hold" rating on its stock and a price target of $52.

The bank said that its rating is based on Illumina's valuation relative to peers and added that its year-to-date stock performance, which is up nearly 50 percent, reflects the firm's positive growth prospects for its sequencing business but may not fairly discount the risk from its competitors.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

What happens to scientific papers when certain journals are no longer published? Some scientists are trying to make sure they don't disappear forever.

A study in Microbiome finds that heavy drinkers have an unhealthy mix of bacteria in their mouths.

Doctors and patients are still trying to figure out what role at-home genetic testing should play in healthcare, Newsweek says.

In Genome Research this week, mismatch repair deficiency in C. elegans, retracing transcriptions start site evolution in the human genome, and more.